Teva Brings In Ranibizumab Biosimilar As Bioeq Files In Europe
Israeli Firm Announces Broader Commercialization Agreement For Lucentis Rival
Biosimilar Lucentis in Europe is once again in the headlines, as Teva announced a deal to in-license Bioeq and Formycon’s FYB201 ranibizumab candidate in several key global markets.
